U.S. markets closed
  • S&P Futures

    4,132.00
    -0.75 (-0.02%)
     
  • Dow Futures

    33,533.00
    -37.00 (-0.11%)
     
  • Nasdaq Futures

    13,970.00
    -5.75 (-0.04%)
     
  • Russell 2000 Futures

    2,224.70
    -0.20 (-0.01%)
     
  • Crude Oil

    60.63
    +0.45 (+0.75%)
     
  • Gold

    1,745.40
    -2.20 (-0.13%)
     
  • Silver

    25.48
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1965
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • Vix

    16.65
    -0.26 (-1.54%)
     
  • GBP/USD

    1.3768
    +0.0016 (+0.11%)
     
  • USD/JPY

    108.8500
    -0.1980 (-0.18%)
     
  • BTC-USD

    63,657.45
    +2,990.93 (+4.93%)
     
  • CMC Crypto 200

    1,372.85
    +78.86 (+6.09%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,649.85
    +111.15 (+0.38%)
     

GW Pharmaceuticals' Epidyolex Wins EU Positive Opinion For Seizures Disorder

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for GW Pharmaceuticals Plc's (NASDAQ: GWPH) Epidyolex (cannabidiol). It is an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC) for patients two years of age and older.

  • TSC is characterized by benign tumors that grow in the body's vital organs, including the brain, skin, heart, eyes, kidneys, and lungs, and in which epilepsy is the most common neurological feature.

  • The condition is typically diagnosed in childhood.

  • The EMA approved GW's cannabidiol oral solution in September 2019 as adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

  • Price Action: GWPH is up 0.1% at $215.05 in market trading hours on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.